Clinical Trial Update: Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating dual-targeting CAR-NK cells against MSLN, FRα, and MUC16 for recurrent epithelial ovarian cancer, primary peritoneal cancer,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• CAR-NK cells targeting MSLN, FRα, and MUC16

Snippet

Sponsor: Beijing Biotech | Conditions: Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma | Phase 1, Phase 2 | Status: RECRUITING